Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
3
×
national blog main
boston
boston blog main
fda
abaloparatide
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
amgen
aminolevulinic acid
andrew berens
avapritinib
biotech
blueprint medicines
boston top stories
cancer
deciphera pharmaceuticals
drugs
europe blog main
europe top stories
european commission
gastrointestinal stromal tumor
gist
givosiran
gleevec
imatinib
national
onpattro
osteoporosis
patisiran
paul matteis
radius health
regorafenib
ripretinib
rna interference
romosozumab
san francisco blog main
san francisco top stories
What
approval
3
×
drug
3
×
medicine
3
×
fda
nod
seek
ago
alnylam
amgen
amgen’s
announced
blueprint
cancer
carries
chasing
deadly
deciphera
developed
europe
european
filing
forms
gi
heart
indicated
interference
marketing
morning
osteoporosis
pharamceuticals
pharmaceuticals
plans
quick
raise
risk
rna
rnai
second
speedy
treats
Language
unset
Current search:
medicine
×
drug
×
approval
×
" life sciences "
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug